FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Stephens Kristin
2. Date of Event Requiring Statement (Month/Day/Year)
06/08/2021
3. Issuer Name and Ticker or Trading Symbol
Syros Pharmaceuticals, Inc. [SYRS]
(Last)
(First)
(Middle)
C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Development Officer
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

CAMBRIDGE, MA 02140
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 45,000 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (2) 10/20/2025 Common Stock 20,000 $ 6.94 D  
Stock Option (right to buy)   (2) 03/30/2026 Common Stock 6,666 $ 8.51 D  
Stock Option (right to buy)   (2) 05/31/2026 Common Stock 6,666 $ 11.66 D  
Stock Option (right to buy)   (2) 09/14/2026 Common Stock 12,750 $ 12.59 D  
Stock Option (right to buy)   (2) 02/09/2027 Common Stock 38,200 $ 10.9 D  
Stock Option (right to buy)   (3) 02/15/2028 Common Stock 30,000 $ 10.09 D  
Stock Option (right to buy)   (4) 08/30/2028 Common Stock 7,200 $ 12.29 D  
Stock Option (right to buy)   (5) 02/11/2029 Common Stock 53,350 $ 6.71 D  
Stock Option (right to buy)   (6) 02/12/2030 Common Stock 84,000 $ 7.54 D  
Stock Option (right to buy)   (7) 06/10/2030 Common Stock 10,000 $ 9.17 D  
Stock Option (right to buy)   (8) 02/16/2031 Common Stock 94,000 $ 11.41 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Stephens Kristin
C/O SYROS PHARMACEUTICALS, INC.
35 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140
      Chief Development Officer  

Signatures

/s/ Kristin Stephens 06/10/2021
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The reporting person was granted restricted stock units, with each unit representing the right to receive one share of the issuer's common stock. These restricted stock units will vest in full on March 31, 2022.
(2) This option is fully vested.
(3) Option vested as to 25% of the shares on February 28, 2019 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2022.
(4) Option vested as to 25% of the shares on August 31, 2019 with the remaining shares vesting in equal monthly installments thereafter through August 31, 2022.
(5) Option vested as to 25% of the shares on February 29, 2020 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2023.
(6) Option vested as to 25% of the shares on February 28, 2021 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2024.
(7) Option vests as to 25% of the shares on June 11, 2021 with the remaining shares vesting in equal monthly installments thereafter through June 11, 2024.
(8) Option vests as to 25% of the shares on February 28, 2022 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2025.
 
Remarks:
Exhibit 24: Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.